Individuals with both elevated Lp(a) and LDL-C have a higher risk of aortic valve calcification (AVC) and aortic stenosis (AS) than those with raised levels of either lipoprotein alone and may, therefore, be most likely to benefit from novel Lp(a)-lowering agents and/or combined LDL-C and Lp(a) lowering.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.